GlassScriptPhysician profile
Adam M Davis
NPI 1235691825
$1,658.65
in general payments reported to CMS, 2019-2025
23 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $253 · 2023: $813 · 2024: $233 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.13 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $188.36 | 2022-2025 | |
| Abbvie INC. | $184.97 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $182.27 | 2023-2025 | Mounjaro, Emgality, Zepbound |
| Idorsia Pharmaceuticals US INC | $110.94 | 2022-2023 | Quviviq |
| Pfizer INC. | $89.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $84.71 | 2023-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.53 | 2022-2024 | Jardiance |
| Axsome Therapeutics, INC. | $69.20 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $51.87 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $48.43 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $37.32 | 2022 | |
| Amgen INC. | $34.48 | 2022-2024 | Evenity, Prolia |
| Grifols USA, LLC | $27.34 | 2023 | Prolastin-C Liquid |
| Verona Pharma, INC. | $22.15 | 2025 | Ohtuvayre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.76 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.69 | 2022 | |
| Merck Sharp & Dohme LLC | $16.13 | 2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Edwards Lifesciences Corporation | $14.93 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $14.78 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.72 | 2022 | |
| Dynavax Technologies Corporation | $12.51 | 2023 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.